Open the map

Intuitive SurgicalISRG

Medtech & devices · NASDAQ · USA

$415.41
Up 0.2% todayClose

Down 26.8% this year but +2.6% since June 26, behind the life science sector at +10.7%. Intuitive Surgical is one of 11 companies Sectivia maps in Medtech & devices.

This year
−26.8%
1 year
−6.0%
P/E
46.7
P/S
13.3
P/B
8.1

Price vs the life science sector

since Jun 26ISRGLife science sector, equal weight
Intuitive Surgical (ISRG) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. ISRG: +2.6% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−20%−10%0%+10%Jun 26AugSepOctOct 8ISRG +2.6%Sector +10.7% Intuitive Surgical (ISRG) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. ISRG: +2.6% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−20%−10%0%+10%Jun 26AugSepOct 8ISRG+2.6%Sector+10.7%

Supply chain

No suppliers or customers are mapped for Intuitive Surgical yet.

See the life science value chain →

About Intuitive Surgical

The da Vinci systems brought robot assistance to minimally invasive surgery and are used worldwide. Ion applies the same approach to lung biopsy, and instruments and servicing follow the installed base.

Theme exposure

MedtechSurgical roboticsProcedure growthMinimally invasive surgery

Products

  • da Vinci surgical robots
  • Ion (lung biopsy)
  • Instruments & service

Competitors

Risks

  • High valuation
  • Growing competition in robotic surgery

Same segment: Medtech & devices

Medical equipment and devices, from surgery and cardiology to robotics. Segment 7 of 8 in the Medicine, pharma & life science value chain.

Compare ISRG

Side by side with the largest companies in the same segment.

See where Intuitive Surgical sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →